# Melphalan With BBBD in Treating Patients With Brain Malignancies

> **NCT00253721** · PHASE1 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Metastatic Cancer

## Interventions

- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT00253721
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-05
- **Primary completion:** 2015-12
- **Final completion:** 2016-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Other competing clinical trials affecting enrollment
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253721, "Melphalan With BBBD in Treating Patients With Brain Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00253721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*